EGFR and non-small cell lung carcinoma: (57) observed that EGFR-TKIs combination with WBRT improved both iPFS (11.9 vs 10.2 months, p=0.039) and OS (21.0 vs 16.7 months, p=0.043) in NSCLC patients with EGFR mutations and BMs compared with just -TKIs.